Nystatin Oral Suspension

Manufacturer
NuCare Pharmaceuticals,Inc.
Effective date
2022-02-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
legacy-cache
Hydrated at
2026-08-01 22:08:19

Label at a glance#

ProductNystatin Oral Suspension
Active ingredientNYSTATIN
Label structure10 sections

Indications and uses

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

Dosage and administration

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). T...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei. Structural formula:

structure
structure

Nystatin Oral Suspension is a cherry-mint flavored suspension for oral administration. It contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), carboxymethylcellulose sodium, flavor, glycerin, methylparaben, propylparaben, purified water, saccharin sodium, sodium citrate, and sucrose (50% w/v). May also contain citric acid for pH adjustment.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACODYNAMICS SECTION

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

PHARMACOKINETICS SECTION

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects Category C

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported (See PRECAUTIONS: General).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been reported.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects or superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, light creamy yellow, ready-to-use suspension in 60 mL bottles with calibrated dropper and 473 mL bottles.

It is supplied as follows:

NDC 68071-2644-6 60 mL

Storage

Store at 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]; avoid freezing.

Distributed by:

Lannett Company, Inc.

Philadelphia, PA 19136

L7046

Rev. 09/19

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

pdppdp

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0527-5121-62ML - Milliliter0527-51219f81e1e0-477d-486f-91a9-33390f88744d12020-04-20
0527-5121-70ML - Milliliter0527-51214e5e6839-0e4d-4be3-8f2c-931282132c6f12020-04-20

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68071-264468071-2644-6
0527-5121

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A065148-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A065148-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-2884e616aacf4f…
2026-08-18 06:07:402026-07A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-2887673890dc5c…
2021-03-12 10:30 UTC2021-03A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-283f01610625f2…
2019-09-15 20:21 UTC2019-09A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28b00525d2431f…
2019-07-19 19:46 UTC2019-07A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-283f0d92c62455…
2023-05-13 08:27 UTC2023-05A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28053a50430f4f…
2023-01-26 05:58 UTC2023-01A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-283a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A065148-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2005-06-28f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A065148-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A065148-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A065148-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065148-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A065148-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065148-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065148-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065148-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065148-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065148-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065148-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065148-001AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065148-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065148-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065148-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065148-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065148-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065148-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065148-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065148-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065148-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065148-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065148-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A065148-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065148-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065148-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065148-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A065148-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A065148-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065148-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065148-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065148-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065148-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065148-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065148-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065148-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A065148-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A065148-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A065148-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A065148-001AA1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
2a09c7b4-08c5-0c1d-e063-6394a90a1c94d88d14a4-ef4a-2347-e053-2995a90a0d422024-12-24Adverse reactionsExact identifier
spl set id: d88d14a4-ef4a-2347-e053-2995a90a0d42

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.